Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating adverse events and changes in disease activity for intravenous ABBV-324 in adults with hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• ABBV-324

Snippet

Sponsor: AbbVie | Conditions: Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer | Phase 1 | Status: RECRUITING